Organization
Poseida Therapeutics
6 clinical trials
Clinical trial
Open Label, Multicenter, Long-Term Follow-Up Study for Subjects Treated With P-BCMA-101Status: Active (not recruiting), Estimated PCD: 2032-08-01
Clinical trial
Open-Label, Multicenter, Phase 1 Study to Assess the Safety of P-BCMA-ALLO1 in Subjects With Relapsed / Refractory Multiple Myeloma (MM)Status: Recruiting, Estimated PCD: 2027-12-01
Clinical trial
Open-Label, Multicenter, Phase 1 Study to Assess the Safety of P BCMA-101 in Subjects With Relapsed / Refractory Multiple Myeloma (MM) Followed by a Phase 2 Assessment of Response and Safety (PRIME)Status: Terminated, Estimated PCD: 2022-04-27
Clinical trial
A Phase 1 Dose Escalation and Expanded Cohort Study of P-MUC1C-ALLO1 in Adult Subjects With Advanced or Metastatic Solid TumorsStatus: Recruiting, Estimated PCD: 2026-04-01
Clinical trial
Open-Label, Multicenter, Phase 1 Study to Assess the Safety of P-CD19CD20-ALLO1 in Subjects With Selected Relapsed/Refractory B Cell MalignanciesStatus: Recruiting, Estimated PCD: 2029-03-01
Clinical trial
A Phase 1 Dose Escalation and Expanded Cohort Study of P-PSMA-101 in Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Advanced Salivary Gland Cancers (SGC)Status: Active (not recruiting), Estimated PCD: 2024-10-01